Gilead Sciences (GILD) said Monday that a phase 3 breast cancer study met its primary endpoint, showing that Trodelvy plus Keytruda "significantly" improved progression-free survival compared with Keytruda and chemotherapy.
The safety profile of the Trodelvy-Keytruda combination also showed consistency with the know safety profile of each agent, Gilead said.
The company said overall survival is a key secondary endpoint and was not mature during the progression-free survival analysis, but there was an early trend in improved overall survival with the combination.
Merck (MRK) and Gilead entered into a collaboration in 2021 to evaluate the Trodelvy-Keytruda combination compared to Keytruda plus chemotherapy in patients with previously untreated, inoperable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1, Gilead said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。